Welcome to our dedicated page for Standard BioTools news (Ticker: $LAB), a resource for investors and traders seeking the latest updates and insights on Standard BioTools stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Standard BioTools's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Standard BioTools's position in the market.
Rhea-AI Summary
Standard BioTools Inc. (Nasdaq:LAB) has announced a collaboration agreement with Navignostics AG to develop clinical research applications and service offerings using the Hyperion XTi™ Imaging System. This collaboration aims to expand access to high-quality data in clinical research, particularly in the fight against cancer, emphasizing the need for precision medicine strategies and robust technologies that offer critical biological insights to guide treatment decisions. Navignostics, founded in 2022, is dedicated to revolutionizing personalized diagnostics for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
-
Rhea-AI Summary
Standard BioTools Inc. (Nasdaq: LAB) expects fourth quarter 2023 revenue of approximately $28 million and full year 2023 revenue of approximately $106 million, representing over 10% growth in core revenue and over 40% growth in instrument revenue compared to 2022. The company completed its merger with SomaLogic, Inc., expecting pro forma full year 2023 revenue of approximately $192 million and over $550 million in cash, cash equivalents, and short-term investments as of December 31, 2023. The CEO, Michael Egholm, expressed excitement about the combined company's progress and commitment to building a scalable, profitable suite of differentiated life science tools to accelerate breakthroughs in healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.37%
Tags
-
Rhea-AI Summary
Standard BioTools Inc. (Nasdaq: LAB) completes merger with SomaLogic, creating a leading provider of differentiated multi-omics tools for research. The combined company has a formidable capital structure comprising over $500 million in cash and cash equivalents, aiming to self-fund future growth initiatives. The company is targeting large, high growth markets with a diverse portfolio of life sciences tools and is expected to realize $80 million in annual cost synergies by 2026. Key leadership team appointments have also been made.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
Rhea-AI Summary
Standard BioTools Inc. (Nasdaq: LAB) announced that its stockholders voted to approve all proposals required for the pending merger with SomaLogic (Nasdaq: SLGC) at its Special Meeting of Stockholders. The merger is expected to close on January 5, 2024, subject to satisfaction of certain customary closing conditions. The company's President and CEO, Michael Egholm, expressed gratitude for the stockholders' support and highlighted the potential for significant shareholder value through enhanced scale and a strengthened balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
-
Rhea-AI Summary
SomaLogic, Inc. (Nasdaq: SLGC) announced stockholder approval for the transaction with Standard BioTools Inc. (Nasdaq: LAB), creating a diversified leader in life sciences tools. The merger is expected to close on January 5, 2024, subject to certain closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
-
Rhea-AI Summary
Madryn Asset Management, LP (Madryn) demands SomaLogic, Inc. (Nasdaq: SLGC) to answer key questions related to the repeated adjournments of the Special Meeting of Shareholders pertaining to the proposed merger with Standard BioTools Inc. (Nasdaq: LAB). Madryn believes the Board of Directors have betrayed shareholders by delaying the Special Meeting five times for a covert vote-flipping campaign. Madryn has sent a litigation hold to the SomaLogic Board and urges shareholders interested in changing their vote to contact Madryn or the firm’s proxy solicitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
Rhea-AI Summary
SomaLogic, Inc. (SOMA) faces challenges as fellow shareholders express concerns over the deal consideration and the company's cash assets, leading to last-minute adjournments of a special meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.39%
Tags
-
Rhea-AI Summary
Boston Millennia Partners (Nasdaq: BMP) opposes SomaLogic's (Nasdaq: SLGC) merger with Standard BioTools Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Madryn Asset Management, LP (Madryn) urges shareholders to vote 'AGAINST' the proposed merger between SomaLogic, Inc. (SLGC) and Standard BioTools Inc. (LAB). Four significant shareholders, including the company founder, have openly stated their opposition to the merger, highlighting concerns about undervaluation and a flawed process. The recommendation from proxy advisory service ISS only offered 'cautionary support' for the merger, leaving room for shareholders to vote 'AGAINST' the transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
SomaLogic, Inc. (Nasdaq: SLGC) founders Dr. Larry Gold and Dr. Jason Cleveland express opposition to the proposed merger with Standard BioTools, Inc. (Nasdaq: LAB) in a letter to stockholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.74%
Tags
Standard BioTools Inc.
Nasdaq:LAB
LAB Rankings
LAB Stock Data
947.15M
50.24M
0.69%
56.05%
2.67%
Analytical Laboratory Instrument Manufacturing
Manufacturing
United States of America
SOUTH SAN FRANCISCO
About LAB
fluidigm (nasdaq:fldm) develops, manufactures and markets microfluidic systems for growth markets in the life sciences and in applied markets. fluidigm’s systems consist of instruments, software, integrated fluidic circuits (ifcs), high-performance assays for gene expression and genotyping, and primers for sample preparation for next-generation sequencing. fluidigm technology enables customers to perform thousands of sophisticated biochemical measurements in parallel on samples smaller than the content of a single cell, with nanoliter volumes of reagents, in half the area of a credit card. the company’s integrated customer solutions are designed to significantly simplify experimental workflows, increase throughput and reduce costs while delivering excellent data quality. based in south san francisco, fluidigm offers an exciting and collegial working environment with excellent compensation and benefits, including equity.